[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540656":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":38,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"The Third Xiangya Hospital of Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ECMO treatment group",null,"Critically ill adult patients treated with ECMO using one or more antimicrobial agents",[13],"Device: ECMO treatment",{"label":15,"type":10,"description":16,"interventionNames":10},"Non-ECMO treatment group","Critically ill adult patients using one or more antimicrobial agents not receving ECMO",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DEVICE","ECMO treatment","Critically ill patients were treated with ECMO while receiving antimicrobial therapy",[9],[24],{"name":25,"affiliation":26,"role":27},"Jingjing Liu","Xiangya Third Hospital, Central South University","STUDY_CHAIR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Jingjing Liu, Doctor","CONTACT","+86 0731-88618170","ivljingjing@126.com",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Shengnan Zhang","+86 18084668240","secnanzhang@gmail.com",[39],{"facility":26,"status":10,"city":40,"state":41,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Changsha","Hunan","China","CN",{"type":45,"coordinates":46},"Point",[47,48],112.97087,28.19874,{"lat":48,"lon":47},[51],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540656","pkpd-study-of-anti-infective-drugs-in-critically-ill-patients-receiving-extracorporeal-membrane-oxygenation-treatment-100540656",false,"NCT06319677","PK\u002FPD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment","PK\u002FPD Study of Antibiotics in Critically Ill Patients Receiving ECMO","ECMO","Inclusion Criteria:\n\n1. Written informed consent was obtained from the patient or family member\n2. Patients who are undergoing ECMO or not\n3. Anti-infection treatment indications\n\nExclusion Criteria:\n\n1. Patients under 18 years of age or pregnant\n2. Information on antimicrobial therapy and ECMO support is incomplete\n3. Presence of other circumstances that make participation in this study inappropriate","ALL","18 Years",{"count":65,"type":66},50,"ESTIMATED","OBSERVATIONAL","Extracorporeal membrane pulmonary oxygenation (ECMO) may provide partial or complete support for organ replacement in patients with severe cardiopulmonary failure, buying time for further management of the primary disease. However, ECMO may significantly alter the pharmacokinetic and pharmacodynamic profiles of critically ill patients, affecting the safety and efficacy of drug therapy. This prospective observational study aims to investigate the impact of ECMO treatment on the pharmacokinetics and pharmacodynamics of antimicrobial drugs in critically ill adult patients. Investigators intend to establish a Population Pharmacokinetic (POP PK) and Pharmacokinetic\u002FPharmacodynamic (PK\u002FPD) model by prospectively collecting blood samples from patients and relevant treatment data. The primary objective is to quantitatively characterize the pharmacokinetic profiles of critically ill patients undergoing ECMO support and provide model-based recommendations for drug regimens tailored to critically ill patients.",[70,71],"Critical Illness","Extracorporeal Membrane Oxygenation Complication",[70,60,73],"Population Pharmacokinetics","NOT_YET_RECRUITING","2024-03-19",{"date":77,"type":78},"2024-03-20","ACTUAL",{"date":80,"type":66},"2024-05-01",{"date":82,"type":66},"2027-05-01",{"name":5,"class":6},1]